Personal information

Other IDs

Loop profile: 721953

Activities

Collapse all

Employment (1)

UT Southwestern Medical Center: Dallas, TX, US

2018-08 to present | Postdoctoral Researcher (Simmons Comprehensive Cancer Center)
Employment
Source: Self-asserted source
Dhivya Sudhan

Works (10)

Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer.

Nature communications
2019-03 | Journal article
DOI: 10.1038/s41467-019-09068-2
PMID: 30914635
PMC: PMC6435685
Contributors: Formisano L; Lu Y; Servetto A; Hanker AB; Jansen VM; Bauer JA; Sudhan DR; Guerrero-Zotano AL; Croessmann S; Guo Y et al.
Source: Self-asserted source
Dhivya Sudhan via Europe PubMed Central

Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research
2018-10 | Journal article
DOI: 10.1158/1078-0432.ccr-18-1544
PMID: 30314968
Contributors: Croessmann S; Formisano L; Kinch LN; Gonzalez-Ericsson PI; Sudhan DR; Nagy RJ; Mathew A; Bernicker EH; Cristofanilli M; He J et al.
Source: Self-asserted source
Dhivya Sudhan via Europe PubMed Central

Extended Adjuvant Therapy with Neratinib Plus Fulvestrant Blocks ER/HER2 Crosstalk and Maintains Complete Responses of ER+/HER2+ Breast Cancers: Implications to the ExteNET Trial.

Clinical cancer research : an official journal of the American Association for Cancer Research
2018-10 | Journal article
DOI: 10.1158/1078-0432.ccr-18-1131
PMID: 30274983
Contributors: Sudhan DR; Schwarz LJ; Guerrero-Zotano A; Formisano L; Nixon MJ; Croessmann S; González Ericsson PI; Sanders M; Balko JM; Avogadri-Connors F et al.
Source: Self-asserted source
Dhivya Sudhan via Europe PubMed Central

Neratinib: Inching Up on the Cure Rate of HER2+ Breast Cancer?

Clinical cancer research : an official journal of the American Association for Cancer Research
2018-05 | Journal article
DOI: 10.1158/1078-0432.ccr-18-1114
PMID: 29802101
Contributors: Unni N; Sudhan DR; Arteaga CL
Source: Self-asserted source
Dhivya Sudhan via Europe PubMed Central

Therapeutic potential of adipose stem cell-derived conditioned medium against pulmonary hypertension and lung fibrosis.

British journal of pharmacology
2016-08 | Journal article
DOI: 10.1111/bph.13562
PMID: 27448286
PMC: PMC5275771
Contributors: Rathinasabapathy A; Bruce E; Espejo A; Horowitz A; Sudhan DR; Nair A; Guzzo D; Francis J; Raizada MK; Shenoy V et al.
Source: Self-asserted source
Dhivya Sudhan via Europe PubMed Central

Cathepsin L in tumor angiogenesis and its therapeutic intervention by the small molecule inhibitor KGP94.

Clinical & experimental metastasis
2016-04 | Journal article
DOI: 10.1007/s10585-016-9790-1
PMID: 27055649
PMC: PMC5378387
Contributors: Sudhan DR; Rabaglino MB; Wood CE; Siemann DW
Source: Self-asserted source
Dhivya Sudhan via Europe PubMed Central

Cathepsin L inactivation leads to multimodal inhibition of prostate cancer cell dissemination in a preclinical bone metastasis model.

International journal of cancer
2016-02 | Journal article
DOI: 10.1002/ijc.29992
PMID: 26757413
PMC: PMC4805507
Contributors: Sudhan DR; Pampo C; Rice L; Siemann DW
Source: Self-asserted source
Dhivya Sudhan via Europe PubMed Central

Synthesis and biochemical evaluation of benzoylbenzophenone thiosemicarbazone analogues as potent and selective inhibitors of cathepsin L.

Bioorganic & medicinal chemistry
2015-09 | Journal article
DOI: 10.1016/j.bmc.2015.09.036
PMID: 26462052
PMC: PMC4824049
Contributors: Parker EN; Song J; Kishore Kumar GD; Odutola SO; Chavarria GE; Charlton-Sevcik AK; Strecker TE; Barnes AL; Sudhan DR; Wittenborn TR et al.
Source: Self-asserted source
Dhivya Sudhan via Europe PubMed Central

Cathepsin L targeting in cancer treatment.

Pharmacology & therapeutics
2015-08 | Journal article
DOI: 10.1016/j.pharmthera.2015.08.007
PMID: 26299995
PMC: PMC4624022
Contributors: Sudhan DR; Siemann DW
Source: Self-asserted source
Dhivya Sudhan via Europe PubMed Central

Cathepsin L inhibition by the small molecule KGP94 suppresses tumor microenvironment enhanced metastasis associated cell functions of prostate and breast cancer cells.

Clinical & experimental metastasis
2013-06 | Journal article
DOI: 10.1007/s10585-013-9590-9
PMID: 23748470
PMC: PMC3823630
Contributors: Sudhan DR; Siemann DW
Source: Self-asserted source
Dhivya Sudhan via Europe PubMed Central

Peer review (2 reviews for 1 publication/grant)

Review activity for Molecular and cellular biochemistry. (2)
How many people are using ORCID?